Brought to you by 
Sangamo licenses Biogen Idec rights to hemoglobinopathy treatments; rights transferred to Bioverativ
06 Jan 2022
Executive Summary
Sangamo BioSciences Inc. (therapeutic DNA-binding proteins) licensed Biogen Idec Inc. exclusive worldwide rights to develop and commercialize treatments for sickle cell disease (SCD) and beta-thalassemia. Biogen also received an exclusive, royalty-bearing license--with the right to sublicense--to Sangamo’s zinc finger nuclease (ZFN) technology platform, plus a nonexclusive, worldwide, royalty-free license--and sublicensing rights--to certain other IP developed under the agreement.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sangamo licenses Biogen Idec rights to hemoglobinopathy treatments; rights transferred to Bioverativ
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice